

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Kemp, David E.	POSITION TITLE Instructor of Psychiatry K-12 Multidisciplinary Research Scholar		
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Kent State University, Kent, Ohio	BS	1996-1998	Integrated Life Science
Northeastern Ohio Universities College of Medicine, Rootstown, Ohio	MD	1998-2002	Medicine
Northwestern University, Chicago, Illinois	Residency	2002-2006	Psychiatry
Case Western Reserve University, Cleveland, Ohio	Fellowship	2006-2007	Mood Disorders Research

**A. Positions and Honors.****Positions and Employment**

2002 - 2003	Intern, Department of Psychiatry, Northwestern University, Chicago, IL
2003 - 2006	Resident, Department of Psychiatry, Northwestern University, Chicago, IL
2004 - 2006	Resource Physician, Evanston Northwestern Healthcare, Evanston, IL
2006 - 2007	Fellow, Bipolar Disorders Intervention and Services Research Center, Case Western Reserve University, Cleveland, OH
2007 -	Instructor of Psychiatry, Case Western Reserve University, Cleveland, OH

**Other Professional Experience and Membership**

2001-	American Psychiatric Association, Member
2004 - 2006	Program and Events Committee, Illinois Psychiatric Society
2004 - 2006	Deputy Representative to the Area IV Council, Illinois Psychiatric Society
2006-	International Society for Bipolar Disorders, Member
2006-	Residency Education Planning Committee, Case Western Reserve University
2007-	P20 Steering Committee, Ex-officio Member

**Honors**

1998	Summa Cum Laude, Kent State University
2002	Excellence in Psychiatry Award, Northeastern Ohio Universities College of Medicine
2004	Travel Fellowship to Attend the New Clinical Drug Evaluation Unit, Eli Lilly and Company
2005	Emory University Psychiatry Residents' Symposium Travel Award
2005	Dr. Virginia Tarlow Award in Psychiatry for Outstanding Performance on the National Psychiatry Resident-in-Training Examination
2006	Workshop on Clinical Trials in Psychopharmacology Travel Fellowship, American Society of Clinical Psychopharmacology
2006	American Psychiatric Association Research Colloquium for Young Investigators
2006	Henry P. Laughlin Fellow of The American College of Psychiatrists
2006	Northwestern University Scholar's Day Award: "Best PGY-IV Manuscript"
2007	John C. and Sally S. Morley Family Foundation Award: "Achieving Remission and Recovery in Depression: The Influence of Metabolic Syndrome on Treatment Outcomes"
2007	Career Development Institute for Bipolar Disorder Award
2007	New Clinical Drug Evaluation Unit New Investigator Award

## B. Selected Publications (in chronological order).

1. **Kemp DE** and Franco KN. Possible leukopenia associated with long-term use of echinacea. *Journal of the American Board of Family Practice*. 2002;15:417-419.
2. **Kemp DE**, Malhotra S, Franco KN, Tesar G, Bronson DL. Heart disease and depression: Don't ignore the relationship. *Cleveland Clinic Journal of Medicine*. 2003;70:745-754.
3. Calabrese JR, Muzina DJ, **Kemp DE**, Sachs GS, Thompson TR, Klingman D, Reed ML, Hirschfeld RM. Predictors of bipolar disorder risk among patients currently treated for major depression. *Medscape General Medicine*. 2006;8(3) [online journal].
4. **Kemp DE**, Gao K, Muzina DJ, Calabrese JR. Progress in the treatment of bipolar depression: Advances and challenges. *Psychiatric Times*. 2006; August, Volume XXIII, No. 9.
5. Muzina DJ, Gajwani P, **Kemp DE**, Gao K, Calabrese JR. Antiepileptic drugs for acute bipolar depression: Applying data to clinical practice. *Psychiatric Annals*. 2006;36:637-644.
6. Muzina DJ, **Kemp DE**, Gao K, Gajwani P, Calabrese JR. Atypical antipsychotics in bipolar depression: Applying emerging evidence to clinical practice. *Psychiatric Annals*. 2006;36:646-652.
7. Gilmer WS and **Kemp DE**. STAR\*D: What have we learned thus far? *International Drug Therapy Newsletter*. 2006; 41:75-82.
8. Gajwani P, **Kemp DE**, Muzina DJ, Xia G, Gao K, Calabrese JR. Acute treatment of mania: An update on new medications. *Current Psychiatry Reports*. 2006;8:504-509.
9. Bernson RR, Manthana P, **Kemp DE**. Behavioral neurology and psychiatry. In: Borsody MK ed. *Comprehensive Board Review in Neurology*. Thieme, New York, New York, 2007, pp 154-182.
10. **Kemp DE**, Gao K, Muzina DJ, Gajwani P, Calabrese JR. Trial-based advances in the treatment of bipolar depression. *Progress in Neurotherapeutics and Neuropsychopharmacology*. 2007;2(1):193-212.
11. **Kemp DE**, Gilmer WS, Fleck J, Dago PL. An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder. *CNS Spectrums*. 2007;12(2):106-111.
12. **Kemp DE**, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: Early response and development of akathisia. *Progress in Neuropsychopharmacology and Biological Psychiatry*. 2007;31(2):574-7.
13. **Kemp DE**, Dago PL, Straus JL, Fleck J, Karaffa M, Gilmer WS. Aripiprazole Augmentation for Treatment-Resistant Bipolar Depression: Sustained Remission after 36-Months. *Journal of Clinical Psychopharmacology*. 2007;27(3):304-5.
14. **Kemp DE**, Muzina DJ, Gao K, Calabrese JR. Pharmacological treatments for bipolar depression: Focus on atypical antipsychotics. *Directions in Psychiatry*. 2007;27(2):99-112.
15. Xia G, Gajwani P, Muzina DJ, **Kemp DE**, Gao K, Ganocy SJ, Calabrese JR. Treatment-emergent mania in unipolar and bipolar depression: Focus on repetitive transcranial magnetic stimulation. *International Journal of Neuropsychopharmacology*. In press.
16. Muzina DJ, **Kemp DE**, Yatham LN, Calabrese JR. Bipolar Depression: Diagnosis and treatment. In: Yatham LN ed. *Bipolar Disorder: A clinician's guide to biological treatments*. In press.
17. Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, **Kemp DE**, Bauer AD, Fleck J, Filkowski MM, Stan VA, Kelley M, Dunn RT. Divalproex in the treatment of acute bipolar depression: A double-blind, randomized, placebo-controlled clinical trial. *Journal of Clinical Psychiatry*. In press.

## C. Research Support.

### Ongoing Research Support

5K12RR023264-03

Kemp (PI)

07/01/2007-06/30/2012

Richard Rudick, MD (K-12, PI)

NIH

The Multidisciplinary Clinical Research Training Program is supported through the "NIH Roadmap" and is intended to train junior investigators in the knowledge and skill of conducting multidisciplinary research.

Role: Principal Investigator

Principal Investigator/Program Director (Last, First, Middle): Kemp, David E.

Research Development Award. Kemp (PI) 01/01/2007 – 01/01/2008

International Society for Bipolar Disorders (ISBD)

The ISBD recognizes the vital role of developing the next generation of leaders in the field of bipolar disorder and offers one \$20,000 fellowship award annually to support research in the field of bipolar disorders. The main purpose of this award is to provide an opportunity for a trainee to get training in research methodology that he/she may not have access to otherwise.

Role: Principal Investigator

N/A Kemp (PI) 01/01/2007 – 01/01/2009

John C. and Sally S. Morley Foundation

Influence of Metabolic Syndrome on Treatment Outcomes

This study investigates the impact of metabolic syndrome on symptomatic and functional outcomes among patients with bipolar disorder or major depressive disorder.

Role: Principal Investigator

NCT00194116 Muzina (PI) 07/01/03 - Present

Abbott

Double-Blind, Placebo-Controlled Divalproex Sodium-ER in Bipolar I or II Depression.

This study evaluates whether divalproex extended-release has acute antidepressant efficacy in patients with bipolar disorder who are naïve to mood stabilizers.

Role: Co-Investigator

### **Completed Research Support**

R21 MH-62650 Calabrese (PI) 02/01/02 – 06/30/07

NIH/NIMH

Combination Therapy in Rapid-Cycling Bipolar Disorder

This study evaluates whether triple therapy with three mood stabilizers is more effective than a combination of two mood stabilizers in the maintenance treatment of rapid-cycling bipolar disorder.

Role: Co-Investigator

02T-183 Calabrese (PI) 09/01/02 – 06/30/07

Stanley Foundation

Lithium, Divalproex, and Blinded Lamotrigine Versus Lithium, Divalproex, and Placebo in the Acute and Continuation Care of Patients with Rapid-Cycling Bipolar Disorder Comorbid with Alcohol, Cannabis, and/or Cocaine Abuse or Dependence.

This study evaluates whether triple therapy with three mood stabilizers is more effective than a combination of two mood stabilizers in the maintenance treatment of rapid-cycling bipolar disorder comorbid with substance use disorders.

Role: Co-Investigator

NCT00289523 Leuchter (PI) 03/01/06 – 07/01/06

Aspect Medical System, Inc.

Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression.

The purpose of this study is to evaluate the potential for EEG to predict an individual's response to treatment with antidepressant medications.

Role: Co-Investigator

Principal Investigator/Program Director (Last, First, Middle): Kemp, David E.

44-01102-000 Gilmer (PI) 08/09/04 – 07/28/05  
Neuronetics

A 9-Week, Uncontrolled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of the Neuronetics Model 2100 CRS Repetitive Transcranial Magnetic Stimulation (rTMS) System in Patients with Major Depression Previously Non-Responsive to Active or Sham rTMS Treatment.

This study was designed to test the acute antidepressant efficacy of open rTMS in patients with depression who did not initially respond to double-blind rTMS therapy.

Role: Co-Investigator

44-01101-000 Gilmer (PI) 08/02/04 – 07/28/05  
Neuronetics

A Randomized, Parallel-Group Sham-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of the Neuronetics Model 2100 CRS Repetitive Transcranial Magnetic Stimulation (rTMS) System in Patients with Major Depression.

This study was designed to assess the acute antidepressant efficacy of rTMS in treatment-refractory depression.

Role: Co-Investigator

44-01103-000 Gilmer (PI) 07/29/04 - 07/28/05  
Neuronetics

A 6-Month Open Label Maintenance Study of Patients with Major Depression Previously Responsive to rTMS Treatment with the Neuronetics Model 2100 CRS Repetitive Transcranial Magnetic Stimulation System.

This study was designed to test the maintenance efficacy of rTMS in the treatment of depression.

Role: Co-Investigator

NCT00195845 Ghaemi (PI) 07/01/04 – 06/01/06  
Janssen (Sub-Contract with Cambridge Health Alliance)

A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder  
This study was designed to test whether galantamine is effective at improving impaired cognition in bipolar disorder.

Role: Co-Investigator

NCT00226343 Ghaemi (PI) 6/01/04 – 06/01/06  
Abbott (Sub-Contract with Cambridge Health Alliance)

Double-Blind, Placebo-Controlled Trial of Depakote-ER for Depressive and Anxiety Symptoms in Non Refractory Bipolar Depression.

This study evaluates whether divalproex-ER is efficacious in the treatment of bipolar depression.

Role: Co-Investigator

N01MH90003 Rush (PI) 04/01/01 – 12/31/05  
NIH/ NIMH

Sequenced Treatment Alternatives to Relieve Depression (STAR\*D).

This landmark study was designed to determine the best “next-step” treatments for depressed patients who do not respond satisfactorily to earlier treatment attempts.

Role: Sub-Investigator